If you’ve ever had a physical, you’re familiar with the standard cardiovascular risk assessment. Doctors check your cholesterol, measure your blood pressure, ask about smoking, and plug those numbers into a calculator like the ASCVD risk calculator. It’s the decades-old standard, and it does a decent job of predicting your risk of a heart attack or stroke over the next ten years.

But let’s be honest: that model leaves a lot of people in the dark.

What about the patient who looks perfectly healthy on paper—normal lipids, moderate blood pressure—but has a father who died of a massive heart attack at 45? The traditional models often struggle to identify that individual as high-risk early enough. They lack the necessary predictive power for the vast majority of people who fall into the intermediate-risk category.

This is where genetics steps in. We’re not talking about rare, dramatic mutations like those causing familial hypercholesterolemia. Instead, we’re focusing on the cumulative, additive effect of thousands of common genetic variants, summarized in a single number: the Polygenic Score (PGS). PGS offers a powerful new layer of personalization, allowing us to stratify risk long before cholesterol levels rise or hypertension sets in. It’s the next era of personalized prevention, and it’s already here.

The Science Behind Polygenic Scores for CVD

How do scientists build a score that predicts your heart health based purely on your DNA?

It starts with massive data sets and sophisticated statistics. Researchers use Genome-Wide Association Studies (GWAS), comparing the DNA of millions of people who have, say, Coronary Artery Disease (CAD) against those who don't. They’re looking for tiny single-letter changes in the genetic code—known as Single Nucleotide Polymorphisms (SNPs)—that slightly increase or decrease your risk.

Think of your PGS as a giant, weighted scorecard. Each SNP associated with CAD is assigned a weight based on how strongly it contributes to the disease. Although one SNP might only increase your risk by a fraction of a percent, the PGS aggregates the effects of tens of thousands, or even millions, of these variants.

The final score is the sum of these weighted risks. This contrasts sharply with monogenic testing, which looks for a single, highly penetrant gene mutation. The PGS captures the collective influence of common variants, explaining a substantial portion of the inherited risk for CVD. It gives you a snapshot of your genetic loading, providing an estimate of how susceptible you are to heart disease throughout your entire lifetime.

Clinical Utility and Predictive Power: What the Data Shows

So what does this actually mean for your health? Does adding a PGS truly improve prediction beyond standard blood tests? Absolutely.

Data from massive biobanks confirms that PGS isn't just an academic curiosity. If you fall into the top 1% of the genetic risk distribution for CAD, your risk is nearly five-fold higher than someone with an average score.³ That level of risk is comparable to having a rare, severe monogenic condition like familial hypercholesterolemia—but unlike that rare condition, the high-risk 1% group represents millions of people.

This is a game-changer for identifying high-risk individuals earlier. New research presented at the American Heart Association (AHA) in 2025 demonstrated that adding PGS significantly improved the accuracy of the CVD risk prediction tool PREVENT across all ancestries studied.¹

The public health implications are staggering. One estimate suggests that incorporating PGS to identify and treat an additional 3 million high-risk individuals (aged 40–70) with preventative medication could prevent approximately 100,000 heart attacks, strokes, and fatal heart disease cases over the next decade.¹ We're not talking about marginal improvements; we’re talking about saving lives by intervening earlier and more decisively.

Integrating PGS into Clinical Practice: Opportunities and Hurdles

Where is the PGS most useful in the clinic today?

It shines brightest when risk is ambiguous. Consider the patient who sits in the intermediate-risk category—their traditional scores are borderline, but they have a strong family history that suggests deeper trouble. PGS acts as a powerful risk improver, pushing that patient into a higher-risk category where intensive lifestyle changes or statin therapy are warranted.

The score is also particularly valuable for younger adults (e.g., those under 50).³ In this group, genetics plays a much larger role before lifestyle factors like obesity or high blood pressure have fully manifested. Adding a PGS to a young adult’s risk equation can reclassify about 20% of those previously considered borderline into the statin-eligible intermediate-risk category, while simultaneously down-classifying another 20% to low risk.³ This allows doctors to tailor prevention years, even decades, before a cardiac event might occur.

Standardization and Ancestry Bias

But integrating PGS routinely isn't without significant hurdles.

The primary issue is ancestry bias. The vast majority of the GWAS data used to train existing PGS models comes from individuals of European ancestry. This means the scores often show reduced predictive performance—or portability—in non-European populations, particularly those of African ancestry. We must actively address this bias to prevent worsening existing health disparities.

Another important challenge is the lack of standardization. A 2024 study highlighted that while many different published PGS models performed equivalently at the overall population level, the individual-level agreement was poor across those models.⁴ This means two different labs could give the same person vastly different scores, which is a major obstacle to consistent clinical use. We need regulatory bodies to standardize calculation methods.

The Push for Equitable Scores

The good news is that the scientific community is already addressing these equity concerns head-on.

The key opportunity lies in developing new, more generalizable models using multi-ancestry genetic data. Researchers have successfully developed new scores, such as GPS_{\text{Mult}}, trained using data from five ancestries (African, European, Hispanic, South Asian, and East Asian). This approach has demonstrated increased predictive strength and outperformed previous models across all ancestries tested.⁵

This effort is especially important for high-risk groups. Like, studies on populations of South Asian ancestry—who often face high rates of CAD—show a particularly strong correlation between a high PRS and disease risk, confirming the potential for powerful stratification in these populations.⁵ The National Institute of Health (NIH) recognizes this imperative, making the development of strong, diverse PGS a priority to make sure equitable risk assessment.

Top Recommendations

If you’re considering how PGS might fit into your health approach, here matter recommendations

  • Talk to Your Doctor Discuss your family history and whether a PGS might clarify your risk, especially if you fall into the intermediate-risk category based on traditional factors.
  • Focus on Action A high PGS is not destiny; it is a roadmap. Use the score as motivation to intensify lifestyle changes (diet, exercise) or adhere strictly to pharmacological interventions like statins.
  • Check Ancestry If you are not of European descent, ask your genetic provider about the specific validation data used for their PGS to make sure the score is relevant to your genetic background.

Precision Prevention — The Trajectory

We are witnessing the trajectory toward precision prevention. The future of CVD risk assessment won't just rely on your cholesterol numbers; it will rely on the combined power of your inherited risk (the PGS) alongside AI-driven analysis of your environment and lifestyle data.

We expect to see formal clinical guidelines emerge soon—in fact, the ESC Council on Cardiovascular Genomics is working toward a consensus statement, signaling the move toward formal adoption of PGS into mainstream cardiology practice.²

Genetic risk screening is quickly becoming standard practice, allowing us to intervene decades earlier than ever before. That’s the real promise of the polygenic score: transforming risk assessment from a backward-looking summary of damage already done into a forward-looking tool for proactive, highly targeted health management.

Sources:

1. AHA 2025: New Study from Genomics Shows Polygenic Risk Scores Improve the Accuracy of Cardiovascular Disease Risk Prediction

2. Polygenic Risk Scores and Coronary Artery Disease

3. Polygenic Risk Scores in Coronary Artery Disease

4. Reproducibility of cardiovascular disease polygenic risk scores across models and populations in a large biobank

5. Multi-ancestry polygenic risk scores for coronary artery disease

This article is for informational and educational purposes only. Readers are encouraged to consult qualified professionals and verify details with official sources before making decisions. This content does not constitute professional advice.